Lila Sciences is a technology company.
Lila Sciences has raised $240.0M across 1 funding round.
Lila Sciences has raised $240.0M in total across 1 funding round.
Lila Sciences is an early-stage technology company building the world's first scientific superintelligence platform paired with autonomous AI Science Factories for accelerated discovery in life sciences, chemistry, and materials science.[1][2][3] Its core product, the Autonomous Science platform, integrates generative AI for hypothesis generation, experiment design, and analysis with robotic labs that execute physical experiments in a closed-loop system, continuously learning from results to refine discoveries and produce novel therapeutics, compounds, and materials.[1][2][3][4] The platform serves enterprise partners, researchers, and industries like biotech, energy, and semiconductors by bridging AI predictions with real-world validation, addressing inefficiencies in traditional science such as reproducibility issues and slow experimentation.[1][5] Backed by Flagship Pioneering, Lila has raised approximately $550 million, including a $350 million Series A at over $1.3 billion valuation, fueling rapid growth with demonstrated benchmarks exceeding human and existing AI performance in antibody discovery, genetic medicines, and catalysts.[3][4][5]
Lila Sciences was founded in 2023 within the innovation labs of Flagship Pioneering, a bioplatform company known for creating ventures like Moderna.[3][4] Key figures include CEO Geoffrey von Maltzahn, formerly of Generate Biomedicines, and Molly Gibson, president of future science and co-founder ties via Flagship, who emphasize building an "intelligence operating system for science" through AI, robotics, and labs.[3][4][5][6] The idea emerged from Flagship's recognition of science's core bottleneck: the gap between AI predictions and physical validation amid a reproducibility crisis and inefficient knowledge sharing.[1][3] Lila emerged from stealth in March 2025 with a $200 million seed, quickly scaling via a $350 million Series A led by investors like Nvidia and In-Q-Tel, marking pivotal early traction through superior benchmarks in multi-domain experiments.[3][4][5]
Lila rides the wave of AI's evolution from data consumption to data generation, addressing finite internet datasets by creating real-world scientific data through autonomous experimentation, enabling "scientific superintelligence" to solve grand challenges in health and sustainability.[3][5] Timing aligns with 2025's AI lab boom, post-protein folding advances, amid U.S. priorities in semiconductors, energy, and biotech competitiveness, accelerated by investors like In-Q-Tel and Nvidia.[5] Market forces favoring Lila include science's reproducibility crisis, rising R&D costs, and demand for faster cycles in drug discovery and materials, positioning it to influence the ecosystem by compounding knowledge, reducing redundancy, and powering a programmable scientific method for broader innovation.[1][2][4]
Lila Sciences is poised to scale its AI Science Factories into a ubiquitous platform, expanding Cambridge facilities and partnerships to deliver licensed therapeutics, catalysts, and materials at unprecedented speed.[4][5] Trends like multimodal AI-physical integration and self-play experimentation will amplify its edge, potentially evolving it into the foundational OS for all science R&D amid growing AI verification needs.[4][6] As the divide between prediction and validation narrows, Lila could redefine discovery, amplifying Flagship's legacy from mRNA vaccines to autonomous science.
Lila Sciences has raised $240.0M in total across 1 funding round.
Lila Sciences's investors include 8VC, Alumni Ventures.
Lila Sciences has raised $240.0M across 1 funding round. Most recently, it raised $240.0M Series A in September 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2025 | $240.0M Series A | 8VC, Alumni Ventures |